Ownership and insider activity for Belite Bio, Inc (BLTE): recent transactions by executives and directors. Track how corporate insiders are trading the stock.
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily.
Price
| Price | $152.17 (closing price, November 3, 2026) |
| Market Cap | $6.1B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-10-01 | Scholl Hendrik Peter | S-Sale | 200 | $33K |
| 2026-10-01 | Scholl Hendrik Peter | S-Sale | 24 | $4K |
| 2026-10-01 | Scholl Hendrik Peter | S-Sale | 120 | $20K |
| 2026-10-01 | Scholl Hendrik Peter | S-Sale | 50 | $8K |
| 2026-10-01 | Scholl Hendrik Peter | S-Sale | 78 | $13K |
| 2026-10-01 | Scholl Hendrik Peter | S-Sale | 12 | $2K |
| 2026-10-01 | Scholl Hendrik Peter | S-Sale | 14 | $2K |
| 2026-10-01 | Scholl Hendrik Peter | S-Sale | 2 | $340 |
| 2026-09-04 | Lin Yu-Hsin | S-Sale | 2,635 | $475K |
| 2026-09-04 | Lin Yu-Hsin | S-Sale | 2,587 | $469K |
Balance Sheet (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $25.6M | $17.3M | $42.1M | $88.2M | $31.7M | $352.9M |
| Short-term Investments | 0 | 0 | 0 | 0 | $113.5M | $139.5M |
| Receivables | $40,000 | $23,000 | $19,000 | $867,000 | $594,000 | $718,000 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $25.7M | $17.4M | $42.8M | $89.9M | $147.1M | $494.3M |
| Property, Plant & Equipment | $66,000 | $94,000 | $1.3M | $1.3M | $965,000 | $777,000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | $31,000 | $3.3M | $4.0M | $4.9M |
| Total Assets | $25.7M | $18.3M | $44.3M | $94.6M | $152.1M | $780.6M |
| Accounts Payable | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $972,000 | $1.6M | $2.1M | $3.6M | $6.0M | $9.9M |
| Long-term Debt | $31.8M | $31.8M | 0 | 0 | 0 | 0 |
| Total Liabilities | $32.8M | $33.4M | $2.8M | $4.2M | $6.3M | $10.1M |
| Retained Earnings | -$17.6M | -$27.2M | -$39.9M | -$71.5M | -$107.6M | -$185.3M |
| Total Equity | -$7.0M | -$15.1M | $41.5M | $90.4M | $145.8M | $770.5M |
| Total Debt | $31.8M | $31.8M | $866,000 | $886,000 | $537,000 | $429,000 |
| Net Debt | $6.2M | $14.5M | -$41.2M | -$87.3M | -$144.6M | -$492.0M |
| Working Capital | $24.7M | $15.8M | $40.7M | $86.3M | $141.0M | $484.4M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 33.56 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 319.70 |
Profitability
| Return on Equity | -15.65% |
| Return on Invested Capital | -15.28% |
| Return on Assets | -12.93% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: KOD · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L
Explore sector: Healthcare · Biotechnology
More sections of BLTE: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks